Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Dirk Spitzer
Washington University, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Accuronix Therapeutics
Other : Licensing Agreement/Intellectual property rights from the awardee institution
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the CIRC determined Dr. Spitzer’s personal financial relationship with Accuronix Therapeutics creates a financial conflict of interest due to the following reasons:
• His personal financial relationship with Accuronix Therapeutics is directly related to the research because the research is evaluating a technology he co-invented
• The primary focus of Accuronix Therapeutics is to commercialize the IP being developed and evaluated in the above mentioned research
• As a co-inventor of the technology, he would be entitled to future royalties when the license agreement with Accuronix is executed
• His role in design of the study, analyzing, collecting and reviewing the data, reporting of the results, mentor oversight of the research, and supervision of all individuals involved in the research could directly affect the research
While the CIRC determined Dr. Spitzer has a financial conflict of interest related to the NIH grant, it concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research and adequate protections are in place for the human research participants of the corresponding human study, based on the following reasons:
• The research is basic in nature and in its early stages
• The human study presents relatively little risk to the human research participants because the only involvement is to provide tumor samples for in vitro and in vivo testing
• He has no role in the human study
• Additionally, a plan has been developed to mitigate his financial conflict of interest, which is outlined below.
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER
Pancreatic adenocarcinoma is the fourth most lethal cancer and notoriously resistant to standard chemotherapy. We present here a novel strategy for delivery of small molecules selectively to pancreatic cancer that induce tumor cell death. We propose the rational design and functional validation of several candidate compounds in vitro and in a mouse model of human pancreatic cancer.
Filed on July 08, 2016.
Tell us what you know about Dirk Spitzer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Dirk Spitzer”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Dirk Spitzer | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
| Dirk Spitzer | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
| Dirk Spitzer | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
| Dirk Spitzer | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.